Bishop is a mouthpiece for Missing. His write-ups merely cherry pick public statements from Anavex. There is no evidence of any independent research or analysis. When a seemingly independent third party regurgitates the party line, there are plenty of people willing to believe it. Meanwhile, during the years Bishop has been touting AVXL, shareholders have taking a shellacking.
It's nice to get mentioned in Forbes. Our PDD trial isn't actually "wrapping up", we're about to finish enrollment. But since we expect topline results mid-2020, it's fair to say that the end is not far off.
jtsmgoblue: A great article in a respected Forbes magazine. I believe this may be the beginning of a lot more coverage and does nothing to hurt our cause. Very nicely put by the writer!! All the good news the better to get more big money interests involved in investing. We have been here a long time waiting for factual success and recognition. This is definitely helpful!!!
FYI, the MoneyShow, which contributes to Forbes, still has not released Anavex as a top drug pick for 2020 on their website. Forbes received an advance “heads up” and authorization to publish. The MoneyShow is rolling out their sector picks this week. So, the groundswell of news and awareness of Anavex will continue.